Objective
to evaluate the safety and efficacy of concomitant TAVR and left atrial appendage occlusion with Watchman (LAAO) as compared to TAVR + medical therapy
Study
prospective, open-label multicentre non inferiority randomised trial (margin HR<1.5)
Population
patients with nonvalvular atrial fibrillation
Endpoints
composite of the first occurrence of all-cause death, stroke or life threatening and major bleeding within 2 years
Conclusion
concomitant WATCHMAN LAAO and TAVR is non-inferior to TAVR + medical therapy.
Of note: increased complexity of WATCHMAN LAAO procedure
Kapadia et al. Circulation 2024;149:734-743
